Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.

Author: Tucage Goltijind
Country: Venezuela
Language: English (Spanish)
Genre: Photos
Published (Last): 11 September 2009
Pages: 495
PDF File Size: 13.83 Mb
ePub File Size: 4.90 Mb
ISBN: 224-1-83539-840-3
Downloads: 72329
Price: Free* [*Free Regsitration Required]
Uploader: Samura

Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues would have already been taken care of by the exiting PE firm. Fortis again pushes back date to complete RHT Health deal; auditor resigns.

The PE firm is selling around 1.

We have not given a thought to a pre-IPO funding round. Ltd with returns of almost three times. Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products. Of these revenues, Secondary transactions set the ground for appropriate valuations as there is no information arbitrage unlike in a primary transaction.

Emcure Pharmaceuticals withdraws proposed IPO. These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients.


My Saved Articles Sign in Sign up.

Emcure Pharmaceuticals files DRHP for IPO

Blackstone has exited now. This will alert our moderators to take action Name Reason for reporting: Choose your reason below and click on the Report button. Will be displayed Will not be displayed Will be displayed. Get instant notifications from Economic Times Allow Not now You can switch off notifications anytime using browser settings. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a It is ranked much higher in the therapeutic areas in which it operates.

Thu, Dec 19 British support-services provider Serco Group Plc.

Emcure Pharmaceuticals withdraws proposed IPO

Edited by Joby Puthuparampil Johnson. Private emcurf major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals.

Reliance to buy majority stake in renewable energy services firm Kanoda.

This is the second exit by Blackstone from its India portfolio. Drag according to your convenience. The issue also involves a secondary sale 2. Blackstone Emcure Bain Capital private equity stake. Emcure is ranked the 14th largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical products, according to healthcare services information provider IMS Health India.

Book running lead managers to the issue include Bank of America Merrill Lynch.

Emcure Pharmaceuticals files DRHP for IPO – The Economic Times

Here’s how the world is celebrating Christmas. Your Reason has been Reported to the admin.

  ISO 19790 PDF

NIFTY 50 10, 2. It has subsidiaries in Brazil, DubaiNigeria, Singapore and South Africa and branch offices in Morocco and Russiawhich play an important role in its international operations, the release said. The content may not be copied, broadcast, downloaded and stored emcrue any dthptransmitted, adapted or changed in any way whatsoever without the prior written permission of Mosaic Media Ventures Private Limited.

BSCPL is an infrastructure development company which operates in road, irrigation, real estate and hydro power projects. Of these revenues, By Jasleen Kaur Batra. Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.

Emcure Pharmaceuticals files for IPO; Blackstone to part exit | Reuters

Emcure was the first private equity investment by a Blackstone-managed fund in India. Emcure Pharmaceuticals emcuee Canadian company and its marketing arm Marcan.

Deepti Chaudhary Malvika Joshi. For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs Infibeam calls off pact to acquire Snapdeal unit Unicommerce. Fri, Dec 20